R-2A Activity · President's Budget PB2027

3) Countering Emerging Threats Rapid Acquisition and Investigation of Drugs for Repurposing (CET RAIDR)

Activity a2·Project MT5 — Mitigate (SDD)·PE 0604384BP·Defense-Wide
FY2027 Request
$16.5M
▲ 5.1% vs FY2026
HitchAI read

This activity requests $16.5M in FY2027, 37% of project MT5, up 5.1% on FY2026. The R-2A exhibit describes it across FY2025–FY2027, including what the FY2027 money is planned to buy.

FY2027 Request
$16.5M
▲ 5.1% vs FY2026
FY2026 Enacted
$15.7M
▲ 1.5% vs FY2025
FY2025 Actual
$15.4M
Prior year
Planned work

What the FY2027 request buys

Verbatim from the R-2A exhibit for project MT5 of PE 0604384BP. This is the budget justification's own description of work that has not happened yet — the one thing no other level of the budget carries.

FY2027 planned work

Field multiple data updates to military medical guidelines to support medical rapid response and maintain force regeneration in a chemical or biological emergency. Continue evaluating FDA-approved and/or late-stage products to repurpose as a CB defense MCM.

FY2026 to FY2027 change

Minor increase due to inflation rate adjustment

Before the request year

FY2025–FY2026: what came before

Prior-year accomplishments and current-year plans from the same exhibit. Context for the FY2027 plan, not a series — an activity partitions its project exactly in the request year, but can under-cover it in earlier years.

FY2026 plans — current year

Continue evaluating FDA-approved and/or late-stage products to repurpose as a CB defense MCM. Studies generate safety and efficacy data to support the use of the test product against CB defense symptoms.

FY2025 accomplishments

Fielded multiple military medical guidelines to support medical rapid response and maintain force regeneration in a chemical or biological emergency. Continued evaluating FDA approved and/or late-stage products to repurpose to treat symptoms from chemical and biological threats.

Money

Three years, and no five-year plan

An R-2A activity publishes the prior year, the current year and the budget year. The FYDP outyears exist at project and program-element level and are deliberately absent here rather than inferred. Estimate types are colored and never summed into one figure.

015.4FY25ACTUAL15.7FY26ENACTED16.5FY27REQUEST
Actual Enacted Request
Fiscal YearEstimate TypeAmount ($M)
FY2025Actual15.4
FY2026Enacted15.7
FY2027Request16.5

This activity is 37% of project MT5's FY2027 request and 6.3% of PE 0604384BP's. In the request year the activities under a project sum to it exactly; in the current year they under-cover it in about 9% of cases, so an activity's delta can legitimately exceed its parent's and the two must not be compared row to row.

Where this sits

8 activities in project MT5

Every R-2A line of this project, largest FY2027 request first. Linked where the activity has enough of its own narrative to carry a page; the rest are shown in full on the project page.

3) Countering Emerging Threats Rapid Acquisition and Investigation of Drugs for Repurposing (CET RAIDR) — this activity$16.5M ▲ 5%
2) Anti-Viral Oral Therapeutics (AVO TX) - Non-Clinical Studies$12.5M ▲ 225%
4) Countering Emerging Threats Rapid Acquisition and Investigation of Drugs for Repurposing - Enhanced Biological Defense (CET RAIDR-ENBD)$7.5M ▲ 2%
7) Tactical Contamination Mitigation System (TCMS)$5.1M ▼ 22%
5) Forward Area Mobility Spray System (FAMS-S) - Aircraft Interior Decon (AID)$2.5M NEW
1) Alternative Autoinjector Manufacturer Capability (AUTOINJ) - RAD-A▼ 100%
6) Service Equipment Decontamination System (SEDS)▼ 100%
8) Improved Nerve Agent Treatment System Centrally Acting (INATS CA) - Non-Clinical
Source
FY2027 Office of the Secretary of Defense RDT&E Budget Justification · Exhibit R-2A · PE 0604384BP, project MT5 (President's Budget PB2027). Congressional marks are recorded on the program element, never on an activity.
Machine access
Markdown twin /programs/0604384BP/MT5/a2.md · MCP mcp.hitchintel.combudget_get_activity